FDA Panel Recommends Lifting Restrictions on Six Controversial Peptides

An FDA advisory panel has voted to recommend removing restrictions on six of seven peptides, allowing compounding pharmacies to produce them despite objections from the agency's own scientists. The votes, held July 23-24, approved BPC-157, KPV, TB-500, MOTs-C, epitalon, and semax; only emideltide was rejected Source: Gizmodo. The narrow margins (8-6, 7-5) reflected a deep divide between panel members with ties to the peptide industry and those without Source: The Guardian.

Key Votes and Reactions

• BPC-157, TB-500, KPV, MOTs-C: Approved for compounding, with proponents citing patient access and medical freedom Source: BBC.
• FDA scientists: Argued there is insufficient safety and efficacy data; most data come from animal studies Source: NPR.
• Panel member Dr. Elizabeth Rebello voted no on BPC-157 due to "lack of efficacy data" and safety concerns Source: BBC.

Political and Industry Pressure

The meeting was influenced by Health Secretary Robert F. Kennedy Jr., a self-described "big fan" of peptides who vowed to ease restrictions Source: AP News. Critics note that the panel included members with financial ties to telehealth clinics and compounding pharmacies Source: Al Jazeera. Industry players like Hims & Hers have already prepared for production Source: Wired.

What's Next

The FDA is not bound by the recommendation but typically follows it. If adopted, compounded peptides would become available by prescription, potentially increasing access but also raising concerns about unproven treatments Source: CNN.